Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Abramowicz

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 1998
CD40 ligation prevents neonatal induction of transplantation toleranceV Flamand, V Donckier, F X Demoor, et al.
Transplantation Proceedings|February 1, 1995
OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studiesD Abramowicz, D J Norman, M Goldman, et al.
Transplantation|November 5, 1997
A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapyK M Wissing, E Morelon, C Legendre, et al.
Kidney International. Supplement|January 1, 1996
Prevention of OKT3 nephrotoxicity after kidney transplantationD Abramowicz, L De Pauw, A Le Moine, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 18, 2009
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trialZ Wlodarczyk, J-P Squifflet, M Ostrowski, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 1, 2010
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipientsA Humar, Y Lebranchu, F Vincenti, et al.
The New England Journal of Medicine|June 8, 2000
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)J L Nortier, M C Martinez, H H Schmeiser, et al.
Revue Medicale De Bruxelles|May 24, 2008
[Experience about more than 2000 renal transplantations at the university of Brussels]P Madhoun, M Wissing, N Broeders, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter studyS Vitko, Z Wlodarczyk, L Kyllönen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 25, 2015
Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized StudyR Hellemans, M Hazzan, D Durand, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 1998
CD40 ligation prevents neonatal induction of transplantation toleranceV Flamand, V Donckier, F X Demoor, et al.
Transplantation Proceedings|February 1, 1995
OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studiesD Abramowicz, D J Norman, M Goldman, et al.
Transplantation|November 5, 1997
A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapyK M Wissing, E Morelon, C Legendre, et al.
Kidney International. Supplement|January 1, 1996
Prevention of OKT3 nephrotoxicity after kidney transplantationD Abramowicz, L De Pauw, A Le Moine, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 18, 2009
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trialZ Wlodarczyk, J-P Squifflet, M Ostrowski, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 1, 2010
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipientsA Humar, Y Lebranchu, F Vincenti, et al.
The New England Journal of Medicine|June 8, 2000
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)J L Nortier, M C Martinez, H H Schmeiser, et al.
Revue Medicale De Bruxelles|May 24, 2008
[Experience about more than 2000 renal transplantations at the university of Brussels]P Madhoun, M Wissing, N Broeders, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter studyS Vitko, Z Wlodarczyk, L Kyllönen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 25, 2015
Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized StudyR Hellemans, M Hazzan, D Durand, et al.
Pageof 16